A study has shown that long-term exposure to temozolomide in glioblastoma cells leads to acquired drug resistance, which is related to increased GLUT3, and selective targeting of GLUT3 delays the occurrence of this acquired drug resistance [34]. This evidence concerns the gene SLC2A3 and glioblastoma.